358 related articles for article (PubMed ID: 22869678)
1. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
3. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
7. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[TBL] [Abstract][Full Text] [Related]
11. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G; Gale S; Ponniah T
Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
[TBL] [Abstract][Full Text] [Related]
14. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
15. Kawasaki disease: part II. Complications and treatment.
Bayers S; Shulman ST; Paller AS
J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[TBL] [Abstract][Full Text] [Related]
16. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
18. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K; Gururaj VJ; Park JM; Martin CF
Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment of Kawasaki disease.
Dominguez SR; Anderson MS
Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
[TBL] [Abstract][Full Text] [Related]
20. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
